DDInter557 DDInter1400
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Pazopanib
Dihydroergotamine {u} (Compound) downregulates {v} (Gene) SHB
SHB {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is downregulated by {v} (Disease) and {u} (Disease) associated with {v} (Gene) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Dihydroergotamine {u} (Compound) downregulates {v} (Gene) SHB
SHB {u} (Gene) interacts with {v} (Gene) FGFR1
FGFR1 {u} (Gene) is bound by {v} (Compound) Pazopanib
Dihydroergotamine {u} (Compound) downregulates {v} (Gene) IPO13
IPO13 {u} (Gene) is regulated by {v} (Gene) IL1R2
IL1R2 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Dihydroergotamine {u} (Compound) downregulates {v} (Gene) CTNND1
CTNND1 {u} (Gene) interacts with {v} (Gene) LCK
LCK {u} (Gene) is bound by {v} (Compound) Pazopanib
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pazopanib
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Dihydroergotamine (Compound) downregulates SHB (Gene) and SHB (Gene) is downregulated by Pazopanib (Compound)
Dihydroergotamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is downregulated by kidney cancer (Disease) and ABCB1 (Disease) associated with kidney cancer (Gene) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is downregulated by Pazopanib (Compound)
Dihydroergotamine (Compound) downregulates SHB (Gene) and SHB (Gene) interacts with FGFR1 (Gene) and FGFR1 (Gene) is bound by Pazopanib (Compound)
Dihydroergotamine (Compound) downregulates IPO13 (Gene) and IPO13 (Gene) is regulated by IL1R2 (Gene) and IL1R2 (Gene) is upregulated by Pazopanib (Compound)
Dihydroergotamine (Compound) downregulates CTNND1 (Gene) and CTNND1 (Gene) interacts with LCK (Gene) and LCK (Gene) is bound by Pazopanib (Compound)
Dihydroergotamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Pazopanib